CTLA4 and cancer: Recently, the development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1/programmed death ligand 1 (PD-1/PD-L1) raises new hope for cancer patients (6).